Michel Sadelain, Carl June receive 2024 Breakthrough Prize in Life Sciences

Undergrad intern at MSK poses a profound question: What if Henrietta Lacks had a Black doctor?

Every summer since 2010, ten undergraduate students from diverse backgrounds get the opportunity to explore any curiosities they might have about careers in medicine at Memorial Sloan Kettering Cancer Center.

October 04, 2024

Vol.50 No.37

By Claire Marie Porter

In Brief

Dana-Farber, Fred Hutch, MSK, Hopkins form Cancer AI Alliance

Four NCI-designated cancer centers—Dana-Farber Cancer Institute, Fred Hutch Cancer Center, Memorial Sloan Kettering Cancer Center, and The Sidney Kimmel Comprehensive Cancer Center and Whiting School of Engineering at Johns Hopkins—have joined together and secured funding from AWS, Deloitte, Microsoft, and NVIDIA, to create the Cancer AI Alliance.

October 04, 2024

Vol.50 No.37

In Brief

Tampa General, Mass General Brigham strengthen relationship through BMT, CAR T collaboration

Tampa General Hospital and Mass General Brigham announced a strengthening of their affiliation with the development of new programs and services, including a bone marrow transplant program and CAR T therapy program, at TGH.

September 20, 2024

Vol.50 No.35

Clinical

Factors outside CAR T-cell therapy are associated with increased risk of secondary cancers after the treatment, meta-analysis shows
Subgroup analysis suggests risk of secondary cancers after CAR T-cell therapy is similar to risk after other therapies

A meta-analysis of 25 studies—totaling over 5,000 participants—focused on a question that has been troubling patients, physicians, and regulators: Does treatment with CAR T-cell therapy contribute to the development of secondary cancers?

September 13, 2024

Vol.50 No.34

By McKenzie Prillaman

Clinical Roundup

Five-year study identifies long-term effects of axi-cel CAR T treatment

Axicabtagene ciloleucel, commonly known as axi-cel, is an immunotherapy that uses modified T cells to target and destroy cancer cells. Approved for patients who have not responded to at least two prior lines of therapy, axicabtagene ciloleucel has been a game-changer in treating large B-cell lymphoma.

August 09, 2024

Vol.50 No.32

Clinical Roundup

CD5 deletion enhances the antitumor activity of adoptive T-cell therapies

A new study details the critical influence of CD5, a key immunomodulatory protein, on engineered T-cell therapies, which is the foundational basis of the clinical-stage cell therapy company Vittoria Biotherapeutics’ proprietary Senza5TM platform.

July 26, 2024

Vol.50 No.30

Michel Sadelain, Carl June receive 2024 Breakthrough Prize in Life Sciences

YOU MAY BE INTERESTED IN

Undergrad intern at MSK poses a profound question: What if Henrietta Lacks had a Black doctor?

Dana-Farber, Fred Hutch, MSK, Hopkins form Cancer AI Alliance

Tampa General, Mass General Brigham strengthen relationship through BMT, CAR T collaboration

Factors outside CAR T-cell therapy are associated with increased risk of secondary cancers after the treatment, meta-analysis shows
Subgroup analysis suggests risk of secondary cancers after CAR T-cell therapy is similar to risk after other therapies

Five-year study identifies long-term effects of axi-cel CAR T treatment

CD5 deletion enhances the antitumor activity of adoptive T-cell therapies

Renew today!

Subscriber content

Login

Michel Sadelain, Carl June receive 2024 Breakthrough Prize in Life Sciences

YOU MAY BE INTERESTED IN

Undergrad intern at MSK poses a profound question: What if Henrietta Lacks had a Black doctor?

Dana-Farber, Fred Hutch, MSK, Hopkins form Cancer AI Alliance

Tampa General, Mass General Brigham strengthen relationship through BMT, CAR T collaboration

Factors outside CAR T-cell therapy are associated with increased risk of secondary cancers after the treatment, meta-analysis showsSubgroup analysis suggests risk of secondary cancers after CAR T-cell therapy is similar to risk after other therapies

Five-year study identifies long-term effects of axi-cel CAR T treatment

CD5 deletion enhances the antitumor activity of adoptive T-cell therapies

Login

Factors outside CAR T-cell therapy are associated with increased risk of secondary cancers after the treatment, meta-analysis shows
Subgroup analysis suggests risk of secondary cancers after CAR T-cell therapy is similar to risk after other therapies